Free tool
FAERS Monitor: Bafiertam
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210296 or its brand name (Bafiertam, Monomethyl Fumarate). Reports on generic versions are filed under their own applications.
Reports
935
Serious
127
14% of reports
Hospitalization
52
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- flushing350
- pruritus110
- product dose omission issue83
- nausea76
- abdominal discomfort65
- erythema65
- abdominal pain upper51
- fatigue47
- diarrhoea46
- rash44
- dizziness43
- paraesthesia43
- feeling hot41
- headache40
- multiple sclerosis relapse40
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 73 |
| 2022 | 227 |
| 2023 | 166 |
| 2024 | 318 |
| 2025 | 110 |
| 2026 | 39 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,224 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| flushingSignal | 350 | 77.7 | 71.5 | 26,463 |
| feeling hotSignal | 41 | 15.1 | 11.2 | 525 |
| multiple sclerosis relapseSignal | 40 | 13.1 | 9.7 | 438 |
| abdominal discomfortSignal | 65 | 8.7 | 6.9 | 440 |
| erythemaSignal | 65 | 7.1 | 5.6 | 339 |
| pruritusSignal | 110 | 6.4 | 5.4 | 509 |
| product dose omission issueSignal | 83 | 6.4 | 5.2 | 374 |
| paraesthesiaSignal | 43 | 6.1 | 4.6 | 182 |
| abdominal pain upperSignal | 51 | 5.6 | 4.3 | 189 |
| rashSignal | 44 | 2.3 | 1.7 | 31 |
| nauseaSignal | 76 | 2.2 | 1.7 | 48 |
| dizziness | 43 | 1.9 | 1.4 | 19 |
| diarrhoea | 46 | 1.6 | 1.2 | 10 |
| headache | 40 | 1.4 | 1.1 | 5 |
| fatigue | 47 | 1.4 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.